Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | LPO | P22079 | 3/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4774116 | 0.98 | TSHR (0.34) | TSHRALDH1A1POLBSMN1; SMN2HTT | |
| SCHEMBL28761565 | 0.87 | ALDH1A1 (0.33) | TSHRALDH1A1POLBSMN1; SMN2LMNA | |
| SCHEMBL27930086 | 0.82 | RAB9A (0.38) | TSHRALDH1A1POLBSMN1; SMN2HTT | |
| SCHEMBL3588715 | 0.80 | MAPK1 (0.35) | TSHRSMN1; SMN2 | |
| SCHEMBL28212449 | 0.80 | P2RX4 (0.45) | ALDH1A1SMN1; SMN2LMNAMAPTMEN1 | |
| SCHEMBL27595630 | 0.79 | CYP3A4 (0.35) | TSHRALDH1A1POLBLMNAMAPT | |
| SCHEMBL1405404 | 0.79 | — | — | |
| SCHEMBL4540593 | 0.77 | — | — | |
| SCHEMBL3797610 | 0.76 | — | — | |
| SCHEMBL1838102 | 0.76 | PREP (0.37) | ALDH1A1SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110869363-B | 5-membered and bicyclic heterocyclic amides as ROCK inhibitors | 百时美施贵宝公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-117304183-A | Five-membered and six-membered nitrogen-containing compound, intermediate thereof, preparation method and application | 杭州圣域生物医药科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-117203206-A | GCN2 modulating compounds and uses thereof | 希伯塞尔股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-111278821-B | Spiro compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-111269221-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-114685495-B | N-difluoromethyl diazacyclo selenourea compound with insecticidal, bacteriostatic, herbicidal and anticancer effects and preparation and application thereof | 华南农业大学 | 2023-08-04 | — | — | CN | disclosed |
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| EP-4172156-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | Philip Morris Products S.A. (CH) | 2023-05-03 | — | — | EP | disclosed |
| CN-115698002-A | Compositions and methods for parasite control | 菲利普莫里斯生产公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2007068619-A1 | SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-06-21 | — | — | WO | disclosed |
| EP-1664043-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2006-06-07 | — | — | EP | disclosed |
| CN-1768051-A | Substituted pyrazoles | MERCK PATENT GMBH (DE) | 2006-05-03 | — | — | CN | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005028475-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004101573-A9 | SYNTHESIS OF SUBSTITUTED HETEROCYCLIC COMPOUNDS | CENTRE NAT RECH SCIENT (FR) | 2005-01-06 | — | — | WO | disclosed |
| CN-1284945-A | Substituted pyriding and pyridazine compounds and their pharmaceutical use | AMGEN INC (US) | 2001-02-21 | — | — | CN | disclosed |
| US-4587251-A | Indolo[2,3-a]quinolizine and indolo[2,3-g]cyclopent[a]indolizine derivatives, compositions and methods employing them for treating ulcers | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1986-05-06 | — | — | US | disclosed |
| US-4563464-A | 2-Azabicyclo(2.2.2)octane derivatives and their use as immunosuppressive agents | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1986-01-07 | — | — | US | disclosed |
| EP-0132964-A2 | 2-Azabicyclo[2.2.2]octane derivatives | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1985-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | TRHDE, CUTA, PIGS | TSHR 336/4885ALDH1A1 2870/4885POLB 4283/4885 |
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | TSHR 351/4885ALDH1A1 1178/4885POLB 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.